Isis changes name to Ionis; Ariad gets new CEO; FDA takes on sunlamp beds;

@FiercePharma: Drug costs soar as China tops world ranking in cancer. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Will prosecutors recommend 5000% increase in jail time in specific cases of pharma securities fraud? More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire prepared to walk on Baxalta talks if deal doesn't come soon: WSJ. Story | Follow @CarlyHFierce

> The Medicines Company ($MDCO) has agreed to sell its hemostasis products to Mallinckrodt ($MNK) in a deal that could reach $410 million. Release

> Isis Pharmaceuticals ($ISIS), which has been battling bad vibes from having the same name as the jihadist organization, today said it is changing its moniker to Ionis Pharmaceuticals, and its ticker symbol to IONS. Release

> Paris Panayiotopoulos, who has been president of EMD Serono, will take the top spot at Ariad Pharmaceuticals ($ARIA) upon the departure of founder Harvey Berger who was pushed by activist investors to step down. Story

> Dr. Arnaud Lallouette has been appointed chief executive of Servier Laboratories, the U.K. subsidiary of the French-based pharma firm. Report

Medical Device News

@FierceMedDev: VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report | Follow @FierceMedDev

@EmilyWFierce: Toxin from sea algae impacts memory, behavior in California sea lions: Study. FierceAnimalHealth story | Follow @EmilyWFierce

> FDA approves Zoll's wearable defibrillator for use in children. More

> Gelesis drops IPO, raises $31.5M for pivotal U.S. trial of hydrogel weight-loss capsule. Story

> Philips' Volcano to keep Sacramento site despite 60 manufacturing layoffs. Article

Biotech News

@FierceBiotech: 'Lies, deceit and greed': Martin Shkreli blasted by the feds for Ponzi scheme. More | Follow @FierceBiotech

@JohnCFierce: AstraZeneca hit with another setback as durvalumab disappoints on lung cancer. Report | Follow @JohnCFierce

@DamianFierce: Hear me out: José Mourinho for CEO. | Follow @DamianFierce

> FDA puts off its decision on BioMarin's DMD drug with Sarepta on the docket. Story

> Bristol-Myers flips its HIV pipeline to GlaxoSmithKline's ViiV in a $3B deal. Report

> Navitor grabs a $33M round as it carefully navigates toward the clinic. Article

And Finally... The FDA is taking steps to prevent the use of sunlamp beds by minors. Release

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.